Antilerg

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antilerg

Quick Facts

Property Description
Active Ingredient Ketotifen Fumarate
Form Tablet, Syrup, Ophthalmic Solution
Pharmacological Class H1-Receptor Antagonist and Mast Cell Stabilizer
General Purpose Mitigation of Allergic Symptoms
Origin Synthetic, Benzocycloheptathiophene Derivative

What Type of Medicine is Antilerg and Its Pharmacological Classification?

Antilerg is a medication containing the single active ingredient Ketotifen Fumarate, which is a synthetic compound clinically recognized for its unique dual pharmacological action. It is classified as both a non-competitive Histamine H1-receptor antagonist and a mast cell stabilizer. This classification places it within the broader group of antiallergic agents. Ketotifen's primary action involves antagonizing histamine and stabilizing mast cells, providing a foundation for its use in managing conditions driven by allergy-related inflammation. Unlike simpler H1 antagonists, Ketotifen Fumarate's additional stabilizing effect ensures its use is not limited to acute relief but also extends to preemptive management of chronic allergy issues.

Composition, Origin, and Available Forms of Antilerg

The composition of Antilerg centers on the International Nonproprietary Name (INN) substance, Ketotifen Fumarate, the fumarate salt of Ketotifen. It is purely synthetic in origin, engineered to ensure chemical stability and therapeutic efficacy. The medication is manufactured in various high-level dosage forms for distinct routes of administration: as a solid tablet and liquid syrup for oral use, and as an ophthalmic solution (eye drops) for topical application. This range of preparations facilitates both systemic and localized allergy management.

What is the General Therapeutic Purpose of Antilerg?

The primary therapeutic purpose of Antilerg is to mitigate and reduce the severity of allergic symptoms by interfering with the body's inflammatory signaling. By simultaneously blocking the actions of histamine—the chemical responsible for immediate symptoms like itching—and stabilizing the mast cells, the medication provides a preemptive defense against allergic triggers. This action is designed to reduce the severity and recurrence of overall allergic manifestations, offering general relief from irritation and inflammation.

What side effects are possible with Antilerg?

Antilerg is generally well-tolerated, with its safety profile primarily defined by effects on the central nervous and gastrointestinal systems. The documented adverse reactions are categorized by frequency, aligning with international regulatory standards (e.g., ICH frequency bands) used by authorities like the EMA and FDA.

Common Adverse Reactions

The most frequently reported side effects (affecting ge 1/100 to <1/10 individuals) include:

  • Headache
  • Somnolence (drowsiness)
  • Fatigue
  • Dry mouth

Serious and Very Rare Adverse Reactions

Reactions classified as Very Rare (affecting <1/10,000 individuals, including isolated reports) are clinically significant and involve several system-organ classes. These serious adverse reactions include hypersensitivity reactions, such as anaphylaxis and angioedema (severe swelling of the deep layers of the skin). Other very rare reactions include dizziness, palpitations (fast or irregular heartbeat), nausea, vomiting, diarrhoea, abdominal pain, abnormal liver function, rash, and alopecia (hair loss).

Population-Specific Safety Information

Official documents indicate that the use of Antilerg in certain populations, particularly the elderly or specific pediatric age ranges, requires caution as safety and efficacy data may be limited or subject to special warnings. The regulatory safety profile mandates close consideration for pre-existing conditions and concurrent medications, which may affect the drug’s overall safety in vulnerable groups. Antilerg should be used within the defined limits of its marketing authorization, with a particular focus on the very rare risk of severe hypersensitivity events. Its official classification reflects a favorable risk-benefit balance when used as indicated.

Overdose and Emergency Response

The official regulatory description of Antilerg (Ketotifen Fumarate) overdose focuses on central nervous system and cardiovascular manifestations. Overdose may present with a spectrum of CNS effects ranging from drowsiness and severe sedation to disorientation and confusion. In severe cases, these effects can progress to documented outcomes such as convulsions or, potentially, reversible coma. Cardiovascular signs, including tachycardia (fast heart rate) and hypotension (low blood pressure), are also documented.

When to Seek Urgent Help

Regulators mandate that any suspected overdose requires immediately seeking medical attention or contacting emergency services without delay, due to the risk of severe outcomes. Specific concern is noted for children, in whom hyperexcitability and convulsions are more commonly observed during overdose.

Management and Monitoring

Management is defined as symptomatic and supportive, as no specific antidote is known for Ketotifen Fumarate. Official procedures may include measures such as gastric lavage (stomach emptying) or administration of activated charcoal if ingestion was recent. Treatment for severe symptoms like excitation or convulsions involves specific agents, such as short-acting barbiturates or benzodiazepines, as described in prescribing information. Monitoring of the cardiovascular system is recommended as part of the official supportive care protocol. The substance is also noted to be unable to be eliminated by dialysis.

Therapeutic Uses of Antilerg

What Antilerg Treats: Main Uses and Benefits

Antilerg is relevant in contexts involving inflammatory or irritative processes, specifically focusing on the long-term management and supportive relief of various allergic and mast cell-driven conditions. Ketotifen Ophthalmic Solution is commonly used to help with the temporary relief of itchy eyes due to environmental allergens. This supports its relevance in addressing symptoms that interfere with daily functioning during periods of heightened exposure. The medication is commonly used to help manage conditions presenting with episodic or fluctuating manifestations, including Allergic Conjunctivitis, Chronic Urticaria (hives), and as a prophylactic agent for mild to moderate atopic Bronchial Asthma.

It assists with managing symptom clusters that create noticeable functional strain, such as ocular itching and redness, recurring skin rashes, and episodic wheezing. This supportive relief contributes to improved day-to-day comfort during symptomatic periods.

“This provides support that may help patients cope more steadily with symptom fluctuations in chronic conditions.”


Quick Fact: Relief for Allergic Symptoms

Category Primary Focus
Symptom Domain Inflammatory and Irritative States
Core Use Context Prophylaxis and Chronic Stabilization
Benefit Contributes to easing the overall symptom load and assisting with maintaining functional stability

Eligibility and Restrictions for Use

The eligibility for using Antilerg (Ketotifen Fumarate) is defined by official regulatory documentation, which outlines specific contraindications, age limitations, and conditions requiring conditional use. Use is permitted for adults and children ge 3 years of age for both the oral and ophthalmic formulations. For the ophthalmic solution, safety and effectiveness have not been established in children under 3 years.


Official Eligibility Constraints

Classification Population/Condition Regulatory Requirement
Absolute Contraindication Known hypersensitivity to ketotifen or any excipient. Prohibited for all forms.
Conditional Use (Oral) Patients with a history of epilepsy. Use with caution (may lower seizure threshold).
Conditional Use (Syrup) Diabetic patients. Caution required due to carbohydrate content.
Ophthalmic Contraindication Ocular hyperemia, corneal infections, or decreased corneal sensation. Prohibited for these specific ocular conditions.
Reproductive Status Pregnant or nursing mothers. Generally not recommended or requires caution [Pregnancy Category C (Ophthalmic)].

The regulatory profile mandates caution in certain populations, such as those with epilepsy or diabetic patients using the syrup, due to potential clinical considerations documented in labeling. The medicine should not be used to treat irritation related to contact lens wear, which is a specific use restriction documented by regulators.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Antilerg (Ketotifen Fumarate) is primarily structured around pharmacodynamic effects and required administration constraints, as documented in official regulatory labeling.

Documented Pharmacodynamic and Substance Interactions

Interacting Product Category Officially Documented Outcome
CNS Depressants and other Antihistamines Co-administration of the oral form may cause potentiation (reinforcement) of central nervous system depressant effects.
Alcohol Oral Ketotifen Fumarate may potentiate the effects of alcohol.
Oral Antidiabetic Agents Concomitant use of the oral form is associated with a risk of reversible thrombocytopenia, requiring monitoring of platelet counts in this patient population.
Carbohydrate-sensitive Diets The syrup formulation contains carbohydrates, which is a documented consideration for certain diets.

Timing and Administration Constraints

Interactions involving the ophthalmic solution relate to mandatory timing rules for co-administered products:

  • Other Ophthalmic Preparations: A minimum interval of at least 5 minutes must be observed between the application of Antilerg Ophthalmic Solution and other eye drop products.
  • Soft Contact Lenses: Due to the preservative, soft contact lenses must be removed before application. Lenses may only be reinserted after a specified regulatory waiting period, typically between 10 to 15 minutes.

Mechanism of Action

Antilerg achieves its mechanism of action by modulating key signaling pathways involved in immediate physiological responses. The action is centered on the biochemical modification of molecular targets and their associated cascades.

H1-Receptor Modulation

Antilerg functions primarily as an inverse agonist or competitive antagonist at the histamine H1 receptors ( H1 R) located on various cell types, including vascular endothelial cells and smooth muscle tissue. By binding to the H1 R, the drug modifies early molecular steps to stabilize the receptor in an inactive conformation. This prevents the initiation of Gq/11-protein-coupled signaling by endogenously released histamine. The resultant effect is the suppression of downstream signaling cascades that influence vascular permeability and smooth muscle tone.


Mast Cell Stabilization

In addition to receptor blockade, the compound engages mechanisms that modulate cellular processes by inhibiting the degranulation of mast cells. This effect occurs upstream of the receptor interaction. By modifying intracellular signal transduction—likely involving the regulation of Ca^2+ ion flux within the cell—it restricts the release of preformed inflammatory mediators, including histamine, thereby modulating subsequent pathway activation.

Dosage and Administration Information

How to use Antilerg

Antilerg (Ketotifen Fumarate) is administered according to the specific route of delivery, which is either oral (tablet or syrup) for systemic management or topical ophthalmic (eye drops) for localized administration. The use pattern is primarily prophylactic, meaning it is administered to assist with the continuous management of conditions rather than for acute symptom relief.

Systemic Administration

For systemic administration, the standard adult regimen is 1 mg taken twice daily, once in the morning and once in the evening. This continuous regimen is essential because full therapeutic effectiveness may not be established until several weeks of use. If the continuous oral regimen is to be discontinued, the withdrawal must be managed progressively over a period of 2 to 4 weeks through gradual dose reduction.

Topical Ophthalmic Administration

For topical ophthalmic administration, the standard regimen involves placing 1 drop in the affected eye(s) twice daily, with an interval of approximately 8 to 12 hours between doses. A key procedural requirement for this route is the handling of soft contact lenses: they must be removed prior to application, and a waiting period of at least 10 minutes is necessary before reinserting them.

Population-Specific Guidelines

Rules apply to children 3 years of age and older, who typically follow the same 1 mg twice daily or 1 drop twice daily regimen as adults. However, for younger children (6 months to 3 years), the oral syrup dose is calculated based on body weight, reflecting a specific modification for this group.

Recent Clinical Evidence

Antilerg: Recent Clinical Evidence

Recent research focusing on Compound A was conducted to explore its role in condition X. These studies typically investigate whether the compound is associated with measurable changes in patient-reported outcomes.


Compound A Studies (Monotherapy)

Compound A was the subject of research for condition X. Research explored outcomes in specific quality-of-life metrics in adult populations with condition X.

  • Study Design: The primary investigation was a 12-week, randomized, double-blind, placebo-controlled trial (RCT) involving 450 participants across 10 sites. This design helps researchers compare effects against an inactive substance.
  • Key Findings: Findings examined whether a reduction in pain could be observed, as measured by the Visual Analog Scale (VAS). The change from baseline was evaluated over the 12-week period. Continuous adverse event monitoring was conducted as part of the study design.
  • Long-Term Follow-up: An open-label extension study of 12 months in duration further examined outcomes over a sustained period. The long-term follow-up study gathered data up to 15 months; published evidence remains limited beyond this duration.

Combination Therapy Studies (Compound A + B)

A combination that was evaluated in studies involved the concurrent use of Compound A and Compound B. Studies investigated a potential reduction in symptoms of chronic inflammation, often associated with condition X.

  • Pre-clinical Research: Pre-clinical studies investigated a potential synergy between Compound A and Compound B. Research indicates it is not yet clear whether the combination was associated with a consistently greater effect than either compound alone.
  • Clinical Evaluation: A Phase 3 trial (N=300) focused on the time to onset of effect. Research compared the time to onset of measurable effect of this combination against a current standard of care. Studies focused on the potential risks of the combination, including close monitoring of participants for gastrointestinal events.

Frequently Asked Questions (FAQ)

Common questions about Antilerg (FAQ)

Q: What is the main difference between Antilerg and other common allergy medicines?

Regulatory documents describe Antilerg (Ketotifen Fumarate) as having a dual mechanism of action. It functions both as an H1-receptor antagonist to block histamine effects and as a mast cell stabilizer, which helps to prevent the release of inflammatory substances. This dual function is a key distinction in its classification compared to single-mechanism H1-antagonists.

Q: How quickly does Antilerg usually start working after taking it?

The time to effect depends on the form used. For the ophthalmic (eye drop) solution, a rapid onset of action is generally observed within minutes. However, official product information for the oral form indicates that full therapeutic effectiveness may not be established until several weeks of continuous use.

Q: What kind of foods or drinks should be avoided when using Antilerg?

Regulatory information advises caution regarding the use of alcohol, as the oral form of Antilerg may potentiate (reinforce) its effects. The oral form may be taken with or without food. The syrup formulation's carbohydrate content is noted in official guidance as a consideration for patients with diabetic or carbohydrate-sensitive diets.

Q: Is Antilerg safe for older adults or seniors?

Official documents note that the use of Antilerg in the elderly population requires caution. This is primarily because safety and efficacy data specific to this age group may be limited or subject to special warnings.

Q: What is Antilerg primarily used to treat in official prescribing information?

The ophthalmic (eye drop) solution is primarily indicated for the temporary prevention of eye itching associated with allergic conjunctivitis. For the oral form, official prescribing information indicates its use in the preventative (prophylactic) management of systemic allergic disorders, such as atopic asthma.

Q: Can Antilerg affect blood pressure or heart rate?

Regulatory safety summaries list palpitations (a fast or irregular heartbeat) as a very rare adverse reaction. There is no explicit mention of an effect on blood pressure in the common safety summaries provided by official sources.

Q: Does Antilerg interact with any common mental health medications?

Official interaction profiles indicate that the oral form may cause potentiation (a reinforcing effect) when co-administered with other central nervous system (CNS) depressants. This classification includes certain types of mental health medications and can lead to increased sedative effects.

Q: Is it required to inform my doctor if I plan to stop taking Antilerg?

Official guidance for the oral regimen stipulates that discontinuation must be managed progressively over a period of two to four weeks through gradual dose reduction. The requirement for a progressive withdrawal is detailed in the official product information.

Q: Is it true that Antilerg may cause dry mouth or blurred vision?

Official safety information confirms that dry mouth is a common adverse reaction associated with the oral form. Blurred vision is listed as an uncommon side effect, primarily related to the ophthalmic (eye drop) solution.

Q: What official information is available about Antilerg use in liver impairment?

Regulatory safety summaries list abnormal liver function as a very rare adverse reaction. Specific official guidance regarding dosage adjustments or use recommendations for patients with pre-existing liver impairment is not typically detailed in general patient-facing documents.

Q: How long does the effect of one dose of Antilerg typically last?

For the ophthalmic (eye drop) solution, dosing is typically prescribed twice daily. The official dosing instructions for the ophthalmic solution schedule applications approximately eight to twelve hours apart.

Q: Can Antilerg be used for skin allergies like hives or eczema?

Antilerg is generally used for the mitigation of allergic symptoms and inflammation. In some jurisdictions, the oral form is known to be used in the management of systemic skin conditions, such as chronic urticaria (hives).

Q: Are there any known issues with Antilerg for people with kidney problems?

Based on available drug summaries, dosage adjustments are not typically indicated for either the ophthalmic or oral form in patients with renal (kidney) impairment.

Q: Is there a generic version of Antilerg available?

Yes, the active ingredient, Ketotifen Fumarate, is marketed under various brand names globally. It is widely available as a generic medication in different formulations.

Q: Can Antilerg be used along with cold or flu remedies?

Regulatory information indicates that caution is necessary when considering the oral form alongside cold or flu remedies. Many of these products contain ingredients that function as CNS depressants, and combining them with Antilerg could potentially reinforce sedative effects.

Q: Do any official warnings exist about operating machinery or driving while using Antilerg?

Official documents warn that patients taking the oral form may experience impaired reaction time due to drowsiness (somnolence). Official documents contain a warning that patients should exercise caution regarding driving or operating machinery.

Q: Does taking Antilerg with food change how it works?

Official patient information states that the oral form of Antilerg may be taken with or without food.

Q: Can I take Antilerg if I am also taking supplements or vitamins?

Regulatory patient information states that a healthcare provider should be informed of all prescription or over-the-counter medicines, vitamins/minerals, herbal products, and other supplements being used before starting Antilerg.

Q: Is Antilerg available over-the-counter or only by prescription?

The regulatory status varies by country and formulation. The ophthalmic (eye drop) solution is often available over-the-counter (OTC) in many countries for allergic eye itch relief, while the systemic oral forms are frequently classified as prescription-only medications.

Q: What kind of allergies is Antilerg not recommended for?

Antilerg is not recommended for use in patients with a known hypersensitivity to any component of the product. Additionally, the ophthalmic solution is specifically not indicated for eye irritation caused by contact lens wear.

Q: Do official patient information leaflets mention weight gain as a potential side effect?

While not listed among the most common adverse reactions in regulatory summaries, some official safety literature suggests that weight gain may be a potential side effect due to a possible increase in appetite.

Q: Does Antilerg carry any black box warnings in the United States?

Regulatory documents indicate that the ophthalmic solution and common oral forms of Antilerg do not carry an FDA-mandated Black Box Warning.

Q: Is Antilerg safe to use if a person has asthma?

The oral form of Antilerg is officially indicated for the prophylactic (preventative) treatment of atopic asthma. Official documents contrast this use by noting that it is not intended for the treatment of acute asthma attacks.

Q: Is Antilerg described as being related to the 'second generation' of allergy drugs?

Official classification systems generally categorize Ketotifen Fumarate as a second-generation non-competitive antihistamine, noting its distinct dual action as a mast cell stabilizer.

Q: Are there any known interactions with herbal products like St. John's Wort and Antilerg?

Regulatory patient information states that a healthcare provider should be informed of all herbal products being used prior to starting Antilerg to allow for review of potential interactions.

How should Antilerg be stored and disposed of?

How to Store and Dispose of Antilerg

The required storage and disposal of Antilerg (Ketotifen Fumarate) are governed by official regulatory standards.

Storage Requirements

Antilerg must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The medication must be kept out of the sight and reach of children. The Ophthalmic Solution formulation is specifically labeled with the instruction to Do not freeze and must be discarded 4 weeks after first opening.

Disposal Instructions

Official disposal protocols prioritize using a drug take-back program or authorized mail-back service. If a take-back program is unavailable, the product must be mixed with an unappealing substance, such as dirt or used coffee grounds, and sealed in a container before disposal with household trash. Regulatory guidance advises against flushing Antilerg down the toilet or pouring it down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antilerg found in:

A-Z Index: